Fig 1: Sp1 suppression prevented cardiomyocytes from OGD/R through PARP1 inhibition. The OGD/R-modeled H9c2 cells were treated with Sp1 shRNA-NC, Sp1 shRNA, PARP1 inhibitor AG-14361 and AD-PARP1 adenovirus. (A) Flow cytometry analysis showed that the percentages of necrotic and apoptotic cells when treating H9c2 cells with Sp1 shRNA, Sp1 shRNA-NC and AG-14361. (B) MTT assay was performed to analyze the cell viability of H9c2 cells when treating H9c2 cells with Sp1 shRNA, Sp1 shRNA-NC and AG-14361. (C) Immunofluorescence showed the positive rate of Sp1 when treating H9c2 cells with Sp1 shRNA, Sp1 shRNA-NC and AG-14361. Magnification: 200×. (D) Western blot showed the expression of PARP1 and autophagy related proteins when treating H9c2 cells with Sp1 shRNA, Sp1 shRNA-NC and AD-PARP1 adenovirus. (E) Real-time PCR showed the mRNA level of PARP1 and autophagy related proteins when treating H9c2 cells with Sp1 shRNA, Sp1 shRNA-NC and AD-PARP1 adenovirus. Compared with control group, *P < 0.05, **P < 0.01; compared with OGD/R group, #P < 0.05, ##P < 0.01; compared with OGD/R+AG-14361 group, $P < 0.05, $$P < 0.01. N = 4 for each group.
Fig 2: Metastasis‐associated lung adenocarcinoma transcript 1 (malat1) M5 regulated the expression of specificity protein 1 (SP1) and SP1 target genes. A, malat1 siRNA significantly downregulated SP1 in A549 and H1299 cells, whereas overexpression of malat1 M5 caused accumulation of SP1 determined by immunofluorescence staining. Scale bar, 10 μm. B, After 48 h of transfection with pcDNA‐M5, blank vector pcDNA, si‐malat1 or si‐control in A549 and H1299 cells, total RNAs and protein, respectively, were collected, then (B‐1) RT‐PCR and (B‐2) western blotting were carried out to detect the levels of SP1,vascular endothelial growth factor (VEGF) and urokinase‐type plasminogen activator receptor (uPAR). GAPDH was used as control. B‐3, Relative density of SP1, VEGF and uPAR was plotted (relative to corresponding control) normalized to GAPDH ± SD from 3 independent experiments. ***P < .01. C, Analysis of luciferase intensity in cells cotransfected with pcDNA‐M5, blank vector pcDNA, si‐malat1 or si‐control, then with SP1‐Luc and the Renilla luciferase reporter plasmid. After 24 h of transfection, cells were assayed using a Dual‐Luciferase Reporter Assay System kit (Promega, Madison, WI, USA). All results are from 3 independent experiments. Values are mean ± SD, ***P < .01 compared with values from cells transfected with control
Fig 3: Working model of NOX1-mediated SP1 regulation of CXCL12 in hypoxia and PAH. Working model depicting NOX1 (alongside its critical subunits p22phox, NOXO1, NOXA1, and Rac1/2) induction of CXCL12 via Sp1 following hypoxia. Resultant CXCL12 is postulated to be secreted from cells, leading to downstream promotion of vascular remodeling and PAH symptoms via pro-proliferative metabolic alteration and glucose uptake.
Fig 4: Validation of ETS1, SP1, and WT1 in human LAA and in vitro and in vivo experiments. Representative immunohistochemical staining images of ETS1, SP1and WT1 (A) and quantification (B). Data are expressed as mean ± SD (n = 5 per group). scale bar = 100 μm. (C). Relative mRNA expression levels of ETS1, SP1 and WT1 in human LAA. Data are expressed as mean ± SD (n = 8 per group). (D). Western blot analyses of ETS1, SP1 and WT1 in human LAA and statistical plot. Data are expressed as mean ± SD (n = 6 per group) (E). Relative mRNA expression levels of ETS1, SP1 and WT1 in HL-1 cells treated with saline or Ang II. Data are expressed as mean ± SD (n = 8 per group). (F). Western blot analyses of ETS1, SP1 and WT1 in HL-1 cells treated with saline or Ang II and statistical plot. Data are expressed as mean ± SD (n = 6 per group). (G). Relative mRNA expression levels of ETS1, SP1 and WT1 in LAA of mice administered with saline or Ang II for 4 weeks. Data are expressed as mean ± SD (n = 6 per group). (H). Western blot analyses of ETS1, SP1 and WT1 in LAA of mice administered with saline or Ang II for 4 weeks. Data are expressed as mean ± SD (n = 6 per group).
Fig 5: Structure prediction of SP1 proteins. (A) The secondary structure of SP1 protein. Blue color represents alpha helixes, red color represents beta bridges, and purple represents random coils; (B) The tertiary structure of SP1 protein in various species.
Supplier Page from Abcam for Anti-SP1 antibody